How might regulators evaluate claims about nature-inspired scientific agent?

What do regulators actually check?

Regulators don't care whether an agent is 'nature-inspired'—they care whether it is safe, effective, and consistent. The key is evidence: a clear mechanism of action, reproducible results, and a favorable risk-benefit profile. For example, in the case of phycocyanin, a nature-inspired antidiabetic compound, regulators would look at animal studies showing it increased fasting insulin and decreased fasting blood glucose, glycosylated serum protein, and glycosylated hemoglobin [3]. These are measurable, objective outcomes, not just a story about spirulina being natural.

Similarly, for nanozymes—nanomaterials that mimic natural enzymes—regulators would demand that the catalytic activity is real and comparable to the natural enzyme it imitates. The research shows that by simulating the amino acid microenvironment and metal coordination of natural enzymes, nanozymes can achieve catalytic performance close to or even beyond natural enzymes [4]. That kind of mechanistic detail is what regulators need to see, not just a claim of 'bio-inspired.'

How strong does the evidence need to be?

The bar is high: regulators require robust, reproducible data, often from multiple studies. In the phycocyanin review, only animal and cellular studies were found—no human trials yet [3]. That would be a major limitation for regulatory approval, because animal results don't always translate to humans. Regulators would likely ask for human clinical data before approving it as a therapeutic.

Another pitfall is overstating what 'nature-inspired' means. The biomimicry innovation policy paper notes that despite the growth of biomimicry, what actually drives nature-inspired innovation remains unclear [2]. Regulators would be wary of vague claims that an agent is 'inspired by nature' without a clear, testable mechanism. They would also check for consistency: does the agent perform the same way every time? The nanozyme research emphasizes that random synthesis and screening often yield poor catalysts, and only rational design based on natural enzyme principles produces high-activity nanozymes [4]. That distinction—between a lucky find and a designed, reproducible agent—is exactly what regulators evaluate.

What can regulators learn from different fields?

Across different domains, the same principle holds: nature inspiration is a starting point, not a guarantee. In drug discovery, natural products have led to many anticancer drugs—about 60% of plant-derived anticancer drugs—but they require semisynthetic modification and rigorous testing to become effective, safe medicines [5]. Similarly, nature-inspired micropatterns offer novel functions, but their fabrication and performance must be validated for each application [1]. Regulators would apply the same logic: the inspiration is irrelevant unless the agent meets the same standards as any other product.

The evidence also shows that policy and institutional support matter. The biomimicry paper highlights that industrialized countries dominate nature-inspired innovation because they have proactive policies, while developing countries lag due to coordination failures [2]. For regulators, this means that the evaluation framework should be consistent and transparent, regardless of where the inspiration comes from, to avoid bias and ensure that good ideas—wherever they originate—can be assessed fairly.

About These Sources

This answer is built on 5 peer-reviewed studies — published from 2021 to 2023, 4 in Q1 journals, collectively cited 862 times — selected as the most relevant from 5 studies that passed quality screening, drawn from 36 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions